Even men feel sad after having sex owing to several reasons, according to a recent study which found that men suffer from Postcoital Dysphoria (PCD) which results in sadness, tearfulness or irritability following sex.
“The study breaks down the results of an international anonymous online survey of 1,208 men from Australia, the USA, the UK, Russia, New Zealand, Germany and elsewhere,” said a researcher Joel Maczkowiack in the paper published by the international journal of Sex & Marital Therapy.
The study focused mostly on men in heterosexual relationships, and all of the sexual relationships were consensual.
Co-author Professor Robert Schweitzer said that comments from the men he surveyed included, “I feel empty, I feel unsatisfied, I don’t want to be touched, I want to be left alone.”
Of the 1,207 men surveyed for the study, 41 per cent had experienced PCD, and 20 per cent had experienced it in the previous four weeks.
“Forty-one percent of the participants reported experiencing PCD in their lifetime with 20 percent reporting they had experienced it in the previous four weeks. Up to four percent suffered from PCD on a regular basis,” he added.
“The first three phases of the human sexual response cycle — excitement, plateau, and orgasm — have been the focus of the majority of research to date,” said Schweitzer.
Researchers said that men who participated and who had experienced sadness following sex described experiences ranging from “I don’t want to be touched and want to be left alone” to feeling unsatisfied, “annoyed and very fidgety.
“Another described feeling ’emotionless and empty’ in contrast to the men who experienced the post-coital experience positively, and used descriptors such as a ‘feeling of well-being, satisfaction, contentment’ and closeness to their partner,” he added.
“The experience of the resolution phase remains a bit of a mystery and is therefore poorly understood. It is commonly believed that males and females experience a range of positive emotions including contentment and relaxation immediately following consensual sexual activity,” he added.
Previous studies on PCD experience found that a similar proportion of females had experienced PCD on a regular basis.
But the case with men is not well understood at the moment.
“We would speculate that the reasons are multifactorial, including both biological and psychological factors,” Schweitzer further pointed out.
Anecdotal evidence from clinical settings as well as personal accounts posted on online blogs suggested that PCD did occur amongst males and had the potential to interfere with couple interactions following sex.
With Agency InputsFollow @gorkhapost
New vaginal ring to prevent HIV, pregnancy is safe: Study
An experimental vaginal ring designed to prevent pregnancy and HIV looks safe, according to an early stage study.
The ring is designed to provide 90 days’ protection at a time. The dual-purpose ring releases the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel, said researchers led by Dr Sharon Achilles, of the University of Pittsburgh School of Medicine.
This small, 14-day trial involving 24 women who were not pregnant and not infected with HIV was the first clinical study of the ring.
“We are very encouraged by our findings in this first-in-human study of the dapivirine-levonorgestrel ring,” said Achilles, an assistant professor of obstetrics, gynecology and reproductive sciences.
Its use resulted in sufficient levels of levonorgestrel to prevent pregnancy and adequate levels of dapivirine to reduce risk of HIV infection, the researchers noted.
There were no safety concerns, and the ring was well-tolerated, according to the Microbicide Trials Network study.
The researchers have started a second Phase 1 trial in which women will use the ring for 90 days.
“With a second study underway, we are another step closer to potentially having an easy-to-use product that can provide safe and effective, long-acting protection against both HIV and unintended pregnancy,” Achilles said in a network news release.
The research was funded by the US National Institutes of Health and presented Wednesday (Oct 24) at an HIV prevention conference, in Madrid, Spain.
Research presented at meetings is usually considered preliminary until published in a peer-reviewed medical journal.